Abstract
CD38 expression by B-cell chronic lymphocytic leukemia (B-CLL) cells has been the focus of several recent studies. The aim of this study was to evaluate the prognostic impact of CD38 expression by peripheral blood lymphocytes on progression-free survival after first-line therapy with high-dose chlorambucil in 53 previously untreated patients affected by typical CD5+ CD23+ B-CLL.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ADP-ribosyl Cyclase
-
ADP-ribosyl Cyclase 1
-
Adult
-
Antigens, CD*
-
Antigens, Differentiation / analysis*
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
B-Lymphocytes / chemistry*
-
Chlorambucil / administration & dosage
-
Chlorambucil / therapeutic use*
-
Disease-Free Survival
-
Female
-
Fluorescent Antibody Technique, Indirect
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Life Tables
-
Male
-
Membrane Glycoproteins
-
Middle Aged
-
NAD+ Nucleosidase / analysis*
-
Neoplastic Stem Cells / chemistry*
-
Prognosis
-
Remission Induction
-
Treatment Outcome
Substances
-
Antigens, CD
-
Antigens, Differentiation
-
Antineoplastic Agents, Alkylating
-
Membrane Glycoproteins
-
Chlorambucil
-
ADP-ribosyl Cyclase
-
CD38 protein, human
-
NAD+ Nucleosidase
-
ADP-ribosyl Cyclase 1